Clinical trials: Solid Malignant Tumors
Gastrinoma, Glucagonoma
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00655655
- Testing
- everolimus, vatalanib, pharmacological study
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic
Solid Tumors, Hematologic Malignancies
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
The purpose of this study is to compare the safety and efficacy of carfilzomib, including measuring the amount of the study drug in the blood at certain times following dosing.
- Conditions
- Solid Tumors, Hematologic Malignancies, Hepatic Impairment
- Trial name
- NCT01949545
- Testing
- Carfilzomib
- Where
- 11 sites in United States, France and 2 more
- Volunteers
- 46 people
- Sponsor
- Amgen
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Clinical Trial Navigation to Increase Participation and Diversity in Cancer Clinical Trials
This clinical trial evaluates a clinical trial navigation intervention to help increase participation and diversity in cancer clinical trials.
- Trial name
- GUIDE (NCT06484595)
- Testing
- Best Practice, Patient Navigation
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fred Hutchinson Cancer Center
Solid Tumor
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and have exhausted other therapeutic…
- Trial name
- NCT06603844
- Testing
- CRB-601 monoclonal antibody, Anti-PD-1 monoclonal antibody
- Where
- 26 sites in United States, United Kingdom
- Volunteers
- 156 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
This phase I trial is studying the side effects and best dose of giving ridaforolimus and vorinostat together in treating patients with advanced solid tumors or lymphoma.
- Trial name
- NCT01169532
- Testing
- ridaforolimus, vorinostat, biopsy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Fox Chase Cancer Center
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors…
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor
- Trial name
- NCT01088763
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 12 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
CetuGEX™: Phase 1 Study in Cancer Patients
This was a prospective, open label, multicenter study evaluating the safety, tolerability and pharmacokinetics of CetuGEX™ after intravenous administration in patients with EGFR positive, locally advanced and/or metastatic solid…
- Trial name
- NCT01222637
- Testing
- CetuGEX™
- Where
- 5 sites in Germany, Italy and 1 more
- Volunteers
- 41 people
- Sponsor
- Glycotope GmbH
Solid Tumor, Adult, Metastatic Solid Tumor
SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation
This is a Phase 1 study of BBP-398, a SHP2 inhibitor, in combination with sotorasib, a KRAS-G12C inhibitor (KRAS-G12Ci), in patients with a KRAS-G12C mutation.
- Conditions
- Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer
- Trial name
- Argonaut (NCT05480865)
- Testing
- BBP-398, sotorasib
- Where
- 25 sites in Australia, Denmark and 5 more
- Volunteers
- 28 people
- Sponsor
- Navire Pharma Inc., a BridgeBio company
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well tazemetostat works in treating patients with brain tumors, solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have come back (relapsed) or do not respond to…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma
- Trial name
- NCT03213665
- Testing
- Tazemetostat
- Where
- 117 sites in United States, Puerto Rico
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors
Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function
Panobinostat (LBH589) is a deacetylase inhibitor (DACi) which belongs to a structurally novel cinnamic hydroxamic acid class of compounds.
- Trial name
- NCT00997399
- Testing
- panobinostat (LBH589)
- Where
- 5 sites in United States, Netherlands and 2 more
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Solid Tumour, Ovarian Cancer
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Overall Design: This is a multicenter, open-label, Phase 1/2 study which will be conducted in three arms (as described below). Each arm will be conducted in two parts: a Phase 1 part which will include dose escalation and a Phase…
- Conditions
- Malignant Solid Tumour, Ovarian Cancer, Triple Negative Breast Cancer, Advanced Melanoma
- Trial name
- NCT01618136
- Testing
- E7449 alone, E7449 plus TMZ, E7449 plus carboplatin and paclitaxel
- Where
- 2 sites in United Kingdom
- Volunteers
- 41 people
- Sponsor
- Eisai Limited
Neoplasms
Japanese Phase 1 Study of BMS-844203 (CT322)
The purpose of this clinical study is to evaluate the safety and tolerability of CT-322 monotherapy to determine the recommended dose for phase II and subsequent studies
- Trial name
- NCT01146171
- Testing
- BMS-844203 (CT-322)
- Where
- Japan
- Sponsor
- Bristol-Myers Squibb
Solid Tumor Cancer
Ispinesib In Combination With Capecitabine In Patients With Solid Tumors
The purpose of this study is to determine the dose regimen of Ispinesib in combination with capecitabine in patients with solid tumors.
- Trial name
- NCT00119171
- Testing
- Ispinesib, Capecitabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor
This is a phase I/II, open-label, multi-center, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of SY-5007 administered orally to participants with…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Solid Tumor
- Trial name
- NCT05278364
- Testing
- SY-5007
- Where
- 2 sites in China
- Volunteers
- 184 people
- Sponsor
- Shouyao Holdings (Beijing) Co. LTD
Unspecified Adult Solid Tumor, Protocol Specific
Paclitaxel Combined With Fluorouracil-Uracil and Leucovorin in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00009828
- Testing
- leucovorin calcium, paclitaxel, tegafur-uracil
- Sponsor
- University of Pittsburgh
AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma
Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. This phase II trial is studying how well topotecan hydrochloride works in treating children with meningeal cancer that…
- Conditions
- AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma
- Trial name
- NCT00005811
- Testing
- topotecan hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Bladder Cancer
LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors
This is a Phase 1/2, open-label, multi-center, single arm basket study evaluating the administration of lerapolturev ± anti programmed cell death protein 1 (PD 1)/programmed death-ligand 1 (PD L1) monoclonal antibody (mAb) (which…
- Conditions
- Solid Tumor, Bladder Cancer, Non-muscle-invasive Bladder Cancer
- Trial name
- NCT04690699
- Testing
- Lerapolturev, 5% DDM
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Istari Oncology, Inc.
Malignant Neoplasms
Phase I Clinical Trial of YKYY031 for Injection in Patients With Advanced Solid Tumors
Phase I study of YKYY031 for injection in patients with advanced solid tumors
- Trial name
- YKYY031，tumors (NCT07631793)
- Testing
- YKYY031 group (the first stage), YKYY031 group (the second stage)
- Where
- 2 sites in China
- Volunteers
- 76 people
- Sponsor
- Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
Solid Tumors Harboring MET Amplification
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan.
- Trial name
- NCT07196644
- Testing
- Telisotuzumab Adizutecan
- Where
- 38 sites in United States, Israel and 3 more
- Volunteers
- 100 people
- Sponsor
- AbbVie
Cancer, Metastases
BMS-599626 in Patients With Advanced Solid Malignancies
The purpose of this trial is to identify the highest oral dose of BMS-599626, a drug that is directed against EGFR and HER2 proteins, that can be given safely on a daily schedule of 21 days with a 7 day rest period in patients…
- Trial name
- NCT00095537
- Testing
- panHer
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb